# Sunitinib or Cediranib for Alveolar Soft Part Sarcoma

> **NCT01391962** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 34 (actual)

## Conditions studied

- Sarcoma, Alveolar Soft Part

## Interventions

- **DRUG:** Cediranib
- **DRUG:** Sunitinib
- **OTHER:** Prochlorperazine
- **OTHER:** Promethazine
- **OTHER:** Benzodiazepine
- **OTHER:** Filgrastim
- **OTHER:** Sargramostim
- **OTHER:** Lomotil
- **OTHER:** Loperamide
- **OTHER:** Vitamin B6
- **OTHER:** Aquaphor
- **DRUG:** Acetaminophen
- **DRUG:** Levothyroxine
- **DRUG:** Warfarin

## Key facts

- **NCT ID:** NCT01391962
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-07-18
- **Primary completion:** 2023-11-06
- **Final completion:** 2026-01-16
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2026-02-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01391962

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01391962, "Sunitinib or Cediranib for Alveolar Soft Part Sarcoma". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT01391962. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*